華熙生物(688363.SH):副總經理、首席技術官、核心技術人員李慧良辭職
格隆匯1月5日丨華熙生物(688363.SH)公佈,公司董事會於近日收到公司副總經理、首席技術官、核心技術人員李慧良的書面辭職報吿,其因個人原因辭去公司副總經理、首席技術官職務,不再作為核心技術人員,辭職後其在公司及子公司將不再擔任任何職務;
李慧良與公司不存在涉及職務發明專利等知識產權權屬糾紛或潛在糾紛的情形,其離職不影響公司專利等知識產權權屬的完整性;
李慧良的離職不會對公司核心競爭力和持續經營能力產生重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.